Banco Santander S.A. Sells 927 Shares of Masimo Co. (NASDAQ:MASI)

Banco Santander S.A. lessened its position in shares of Masimo Co. (NASDAQ:MASIGet Rating) by 2.6% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 34,733 shares of the medical equipment provider’s stock after selling 927 shares during the period. Banco Santander S.A. owned approximately 0.06% of Masimo worth $5,055,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Assenagon Asset Management S.A. increased its position in Masimo by 1,864.5% in the 1st quarter. Assenagon Asset Management S.A. now owns 535,812 shares of the medical equipment provider’s stock valued at $77,982,000 after acquiring an additional 508,537 shares during the period. Invesco Ltd. boosted its stake in Masimo by 12.9% during the fourth quarter. Invesco Ltd. now owns 1,307,606 shares of the medical equipment provider’s stock worth $382,840,000 after acquiring an additional 149,083 shares in the last quarter. BlackRock Inc. boosted its stake in Masimo by 1.5% during the fourth quarter. BlackRock Inc. now owns 9,026,374 shares of the medical equipment provider’s stock worth $2,642,740,000 after acquiring an additional 133,072 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Masimo by 62.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 260,047 shares of the medical equipment provider’s stock worth $76,137,000 after acquiring an additional 100,388 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Masimo by 87.4% during the fourth quarter. JPMorgan Chase & Co. now owns 187,685 shares of the medical equipment provider’s stock worth $54,951,000 after acquiring an additional 87,510 shares in the last quarter. Institutional investors own 92.03% of the company’s stock.

Analysts Set New Price Targets

MASI has been the topic of a number of recent research reports. Needham & Company LLC dropped their price objective on shares of Masimo from $205.00 to $163.00 in a research note on Wednesday, May 4th. Piper Sandler dropped their price target on shares of Masimo from $160.00 to $130.00 in a research report on Wednesday, May 4th. Stifel Nicolaus dropped their price target on shares of Masimo from $175.00 to $150.00 in a research report on Wednesday, May 4th. Finally, StockNews.com raised shares of Masimo from a “hold” rating to a “buy” rating in a research report on Wednesday, July 13th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Masimo currently has a consensus rating of “Moderate Buy” and a consensus target price of $179.60.

Masimo Stock Performance

NASDAQ MASI opened at $153.46 on Friday. Masimo Co. has a 52-week low of $112.07 and a 52-week high of $305.21. The company has a 50-day simple moving average of $136.49 and a 200 day simple moving average of $150.77. The company has a market capitalization of $8.52 billion, a PE ratio of 39.65 and a beta of 0.98.

Masimo (NASDAQ:MASIGet Rating) last posted its quarterly earnings data on Tuesday, May 3rd. The medical equipment provider reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.92 by $0.01. The business had revenue of $304.24 million during the quarter, compared to the consensus estimate of $308.04 million. Masimo had a net margin of 17.91% and a return on equity of 15.46%. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.90 earnings per share. As a group, analysts forecast that Masimo Co. will post 4.61 EPS for the current fiscal year.

Masimo Profile

(Get Rating)

Masimo Corporation develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.

Recommended Stories

Institutional Ownership by Quarter for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.